Form 8-K - Current report:
SEC Accession No. 0001558370-23-011750
Filing Date
2023-07-07
Accepted
2023-07-07 16:05:15
Documents
14
Period of Report
2023-07-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20230707x8k.htm   iXBRL 8-K 30129
  Complete submission text file 0001558370-23-011750.txt   243816

Data Files

Seq Description Document Type Size
2 EX-101.SCH sngx-20230707.xsd EX-101.SCH 4050
3 EX-101.DEF sngx-20230707_def.xml EX-101.DEF 3490
4 EX-101.LAB sngx-20230707_lab.xml EX-101.LAB 630
5 EX-101.PRE sngx-20230707_pre.xml EX-101.PRE 10406
8 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20230707x8k_htm.xml XML 4794
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 231076798
SIC: 2834 Pharmaceutical Preparations